复方磺胺甲噁唑在ANCA相关性血管炎中减少复发与感染风险的作用:一项Meta分析
该Meta分析纳入8项对照研究,评估复方磺胺甲噁唑(TMP/SMX)对肉芽肿性多血管炎(GPA)复发率及ANCA相关性血管炎(AAV)感染风险的作用。7项研究(520例)显示TMP/SMX与GPA复发风险降低无关(RR=1.15,95%CI:0.51,2.55;I2=78.5%;P<0.001);1项回顾性队列研究(192例)提示TMP/SMX联合利妥昔单抗预防可显著减少AAV严重感染。
要点
- TMP/SMX未显示降低GPA患者复发风险(RR=1.15,95%CI:0.51,2.55)。
- 按剂量分层(每日两次960mg vs 每周三次)的敏感性分析结果一致。
- TMP/SMX联合利妥昔单抗预防可能减少AAV严重感染,但证据仅来自一项回顾性队列研究。
核心结论
- TMP/SMX与GPA患者复发风险降低无关。
- TMP/SMX可能有助于减少感染性并发症。
研究设计与样本
- 纳入RCT与含对照组的观察性研究,检索MEDLINE、EMBASE、Cochrane Library、Scopus、Web of Science及ClinicalTrials.gov至2020年1月15日。
- 从2907条记录中筛选出8项研究;7项研究(520例患者,其中2项为RCT)评估GPA复发,1项回顾性队列研究(192例)评估AAV感染。
- 采用随机效应Meta分析计算累积风险比(RR)及95%CI。
主要发现
- TMP/SMX与GPA复发风险降低无关(RR=1.15,95%CI:0.51,2.55;I2=78.5%;P<0.001)。
- 按TMP/SMX剂量(每日两次960mg vs 每周三次)进行的敏感性分析证实上述结果。
- 一项回顾性队列研究显示,接受利妥昔单抗治疗的AAV患者同时使用TMP/SMX预防可显著减少严重感染。
关键数值与推荐
- GPA复发风险:RR=1.15,95%CI:0.51,2.55;I2=78.5%;P<0.001。
- 敏感性分析按TMP/SMX剂量分层:每日两次960mg与每周三次比较,结果一致。
- 严重感染减少仅见于一项192例的回顾性队列研究,对象为接受利妥昔单抗的AAV患者。
临床怎么用
- 不应基于现有证据将TMP/SMX作为GPA减少复发的常规预防用药。
- 对接受利妥昔单抗的AAV患者,可考虑TMP/SMX预防以降低严重感染风险,但需结合个体情况。
- 临床决策应权衡TMP/SMX的潜在获益与不良反应,并参考更大样本的前瞻性研究。
局限性
- 纳入研究数量少(8项),评估复发的研究仅7项、共520例,其中仅2项为RCT。
- 复发分析异质性高(I2=78.5%)。
- 感染相关证据仅来自一项回顾性队列研究(192例),证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess available evidence from randomized controlled trials (RCTs) and observational studies including a control group regarding the role of trimethoprim/sulfametoxazole (TMP/SMX) in reducing the relapse rate in patients with granulomatosis with polyangiitis (GPA) and the risk of infections in patients with ANCA-associated vasculitis (AAV). METHODS: MEDLINE, EMBASE, The Cochrane Library databases, Scopus, Web of Science and ClinicalTrials.gov were searched from inception until 15 January 2020 to identify controlled studies assessing the role of TMP/SMX in reducing the rate of relapse in patients with GPA (primary outcome) and the number and/or severity of infections in patients with AAV (secondary outcome). Two reviewers independently selected eligible studies and extracted data. Cumulative risk ratios (RRs) with 95% CI were calculated using a random effect meta-analysis. RESULTS: Eight studies were selected out of 2907 records. Seven studies (520 patients) (of which two were RCTs) assessed the role of TMP/SMX in the relapse rate in patients with GPA. TMP/SMX was not associated with a reduced risk of relapse (RR = 1.15, 95% CI: 0.51, 2.55; I2 = 78.5%; P < 0.001). Sensitivity analysis according to the dose of TMP/SMX (960 mg twice daily vs three times/week) confirmed the results. One retrospective cohort study (192 patients) was identified demonstrating a significant reduction of severe infections in patients with AAV receiving prophylaxis with TMP/SMX in association with rituximab. CONCLUSION: TMP/SMX was not associated with a reduced risk of relapse in patients with GPA. TMP/SMX might be useful in the reduction of infectious complications. PROSPERO DATABASE REGISTRATION CODE: CRD42019118983.
引用
- Monti S, Delvino P, Riboli M, et al. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis. Rheumatology (Oxford). 2021. PMID: 33752235. doi:10.1093/rheumatology/keab267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。